Skip to main content

SciSparc Ltd.

corporate_fare Company Profile

SciSparc Ltd.

SPRC·NASDAQ·Life Sciences·CIK 0001611746

SciSparc Ltd. is a clinical-stage pharmaceutical company that develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110, which is being developed for the treatment of Tourette syndrome and Alzheimer's disease and agitation. Another program, SCI-210, targets autism spectrum disorder and status epilepticus. The company also develops CannAmide, an anti-inflammatory and chronic pain solution. In addition to its drug development, SciSparc Ltd. sells hemp seed oil-based products and other related items. The company has an agreement with Procaps for the development and commercial manufacturing of SCI-110, palmitoylethanolamide oral tablets, and CannAmide in softgel capsule form. SciSparc Ltd. also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial. This trial evaluates the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. Furthermore, the company has a collaboration with Clearmind Medicine Inc. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021.

SciSparc Ltd. (NASDAQ:SPRC) is a publicly traded company in the Life Sciences sector. Wiseek monitors SPRC SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • SciSparc to Acquire Endoscope Patent Portfolio, Issuing 19.99% Equity for Entry into Multi-Billion Dollar Market
  • SciSparc Receives Nasdaq Non-Compliance Notice for Minimum Stockholders' Equity

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$856K
Net Income
-$12.56M
Diluted EPS
$98.07
Op. Cash Flow
-$4.14M
Gross Profit
$631K
Operating Income
-$8.37M
Cash & Equivalents
$4.59M
Total Debt
$356K
Debt / Equity
0.07×
Net Margin
-14.68×
Shares Outstanding
365.44K sh
Source: 20-F · filed 2026-04-29 · accession 0001213900-26-049322

Insider Transactions

SPRC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$7.01
52-week range · as of 2026-06-22 $2.98 – $80.1
Market cap
$4.02M
Volume
669.7K (10.8× avg)
3-mo avg 62K
Live data · 2026-07-29 14:06 UTC · Market open

show_chartPrice Chart

Loading chart...

feed SPRC - Filings & News (Page 2)

SPRC
Jan 13, 2026, 7:10 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.20
Real-time Price: $7.01 info
Change: Reverse Stock Split info
Market Cap: $4.018M info
SPRC
Jan 12, 2026, 4:09 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.45
Real-time Price: $7.01 info
Change: Reverse Stock Split info
Market Cap: $4.018M info